drugset / Trial / NCT07028281

A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors

NCT07028281

Phase 2 Recruiting 120 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.

Timeline

Start
2025-07-08
Primary completion
2028-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody
Subject BP102 Monoclonal antibody
Subject Carboplatin Small molecule
Subject Cisplatin Other / unclassified
Subject SHR-4849 Unknown
Subject SHR-8068 Monoclonal antibody

Indications